SG11201604944PA - Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features - Google Patents

Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Info

Publication number
SG11201604944PA
SG11201604944PA SG11201604944PA SG11201604944PA SG11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA
Authority
SG
Singapore
Prior art keywords
vortioxetine
kappa
activity
treatment
receptor antagonist
Prior art date
Application number
SG11201604944PA
Inventor
Connie Sanchez Morillo
Gennady N Smagin
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201604944P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SG11201604944PA publication Critical patent/SG11201604944PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201604944PA 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features SG11201604944PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16
PCT/EP2014/078515 WO2015091833A1 (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Publications (1)

Publication Number Publication Date
SG11201604944PA true SG11201604944PA (en) 2016-07-28

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201604944PA SG11201604944PA (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Country Status (14)

Country Link
US (1) US10376506B2 (en)
EP (1) EP3082815B1 (en)
JP (1) JP6448645B2 (en)
KR (1) KR20160093025A (en)
CN (1) CN105828821B (en)
AU (1) AU2014368548B2 (en)
CA (1) CA2933733A1 (en)
CL (1) CL2016001570A1 (en)
ES (1) ES2694352T3 (en)
IL (1) IL246253A0 (en)
MX (1) MX368870B (en)
RU (1) RU2679661C1 (en)
SG (1) SG11201604944PA (en)
WO (1) WO2015091833A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478289A1 (en) 2016-07-01 2019-05-08 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
EP3876938A4 (en) * 2018-11-06 2022-08-10 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
AU2002231206A1 (en) * 2000-12-21 2002-07-01 The Mclean Hospital Corporation Treatment of depression
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
UA81749C2 (en) 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
ATE394097T1 (en) * 2002-03-20 2008-05-15 Euro Celtique Sa METHOD OF ADMINISTRATION OF BUPRENORPHINE FOR THE TREATMENT OF DEPRESSION
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2009517393A (en) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド How to treat anxiety
CN101432011A (en) * 2006-02-27 2009-05-13 亚历山大·米哈洛 Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
DK2001456T3 (en) * 2006-04-04 2010-04-12 Emodys Gmbh Use of kappa opioid receptor antagonist-containing compositions for the treatment of dissociative disorders
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
PT2044043E (en) 2006-06-16 2012-03-26 Lundbeck & Co As H 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
UA106752C2 (en) 2009-05-25 2014-10-10 Х. Луннбек А/С producing nalmefene hydrochloride from naltrexone
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
KR101820181B1 (en) 2010-04-30 2018-02-28 다케다 야쿠힌 고교 가부시키가이샤 Enteric tablet
EA022266B1 (en) 2010-11-05 2015-11-30 Х. Лундбекк А/С Method for the manufacturing of naltrexone
US20150342946A1 (en) 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
WO2014170352A1 (en) 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
WO2014170351A1 (en) 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder

Also Published As

Publication number Publication date
WO2015091833A1 (en) 2015-06-25
CN105828821A (en) 2016-08-03
EP3082815B1 (en) 2018-10-03
AU2014368548A1 (en) 2016-06-30
JP6448645B2 (en) 2019-01-09
CA2933733A1 (en) 2015-06-25
ES2694352T3 (en) 2018-12-20
RU2679661C1 (en) 2019-02-12
MX2016007947A (en) 2016-09-09
EP3082815A1 (en) 2016-10-26
RU2016123972A (en) 2018-01-25
US20160310488A1 (en) 2016-10-27
KR20160093025A (en) 2016-08-05
IL246253A0 (en) 2016-07-31
MX368870B (en) 2019-10-21
CN105828821B (en) 2019-04-09
US10376506B2 (en) 2019-08-13
CL2016001570A1 (en) 2016-12-09
JP2016540030A (en) 2016-12-22
AU2014368548B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
HUS2200048I1 (en) Fcrn antagonists and methods of use
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
HK1216380A1 (en) Attachment apparatuses and associated methods of use and manufacture
HK1217428A1 (en) Substituted benzoxazoles and methods of use thereof
RS56531B1 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
HK1213476A1 (en) Substituted triazolopyridines and methods of use thereof
PT3637254T (en) Portable device and method for restricting use of portable device
IL252547A0 (en) Treatment of multiple sclerosis with laquinimod
EP2989538A4 (en) Method and device for managing memory of user device
EP2971292A4 (en) Electrospinning apparatus and methods of use thereof
RS57815B1 (en) Creel threader and method of use
HK1224307A1 (en) Protoxin-ii variants and methods of use -ii
HK1218254A1 (en) Treatment of multiple sclerosis with laquinimod
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
KR102377615B1 (en) Apparatus and methods of use
IL246253A0 (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP3013344A4 (en) Treating an arrhythmia with an opioid antagonist
GB201302105D0 (en) Cover Means and Method of Use Thereof